Maryland-based Novavax makes vaccines by sticking proteins onto microscopic particles. Engineered from the genetic sequence of COVID-19, we used our recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein. The company launched trials for a Covid-19 vaccine in May.

Phase 1 & Phase 2 Trial

In the Phase 1 portion of the Phase 1/2 clinical trial, conducted in Australia, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera.

Novavax announced promising results from two preliminary studies in monkeys and humans. On August 17, they launched a Phase 2b trial in South Africa to evaluate the efficacy of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.

The blinded, placebo-controlled trial on 2,900 people will measure not just the safety of the vaccine but its efficacy. If the trials succeed, Novavax expects to deliver 100 million doses for use in the United States by the first quarter of 2021. In August, an executive at the company said it could make well over a billion doses a year for worldwide demand.

Novavax intends to initiate the Phase 2 portion of this trial in the U.S. and Australia in the near future. This trial will include approximately 1,500 subjects and will include older adults.

Phase 3 Trials

Larger, Phase 3 trials are expected to start in October.

Pipeline:

Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

They have several other vaccines which are in Phase 3 trial such as:

·         NanoFlu™ - Seasonal Influenza Vaccine (Adults Aged 65+ Years)

·         ResVax™ - RSV F Vaccine (Infants via Maternal Immunization) for Respiratory Syncytial Virus (RSV)

Phase 2 trial

·         RSV F Vaccine (Older Adults 60+ Years) for Respiratory Syncytial Virus (RSV)

Phase 1 trial

·         Ebola GP Vaccine for Ebola Virus

Source:

https://novavax.com/

https://novavax.com/our-pipeline